{"id":"dextran","rwe":[{"pmid":"41912870","year":"2026","title":"The lipid transfer protein STARD7 controls intestinal tumor development in a context-dependent manner.","finding":"","journal":"EMBO molecular medicine","studyType":"Clinical Study"},{"pmid":"41911983","year":"2026","title":"Ethnopharmacological basis and combined protection of intestinal barrier function by fucoidan from Sargassum thunbergii and chito-oligosaccharides in DSS-induced colitis.","finding":"","journal":"Journal of ethnopharmacology","studyType":"Clinical Study"},{"pmid":"41909895","year":"2025","title":"Method of oral delivery affects vitamin C-mediated alleviation of colitis in a mouse model.","finding":"","journal":"Gut microbes reports","studyType":"Clinical Study"},{"pmid":"41909465","year":"2026","title":"TIPE2 gene knockdown in mice attenuates experimental colitis by diminishing inflammatory cell infiltration.","finding":"","journal":"Molecular therapy. Nucleic acids","studyType":"Clinical Study"},{"pmid":"41908945","year":"2026","title":"Cordycepin Ameliorates Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice by Inhibiting IL-6/IL-6R-Mediated p38 MAPK and NF-κB Activation Through Adenosine A(2A) Receptor Stimulation.","finding":"","journal":"Drug design, development and therapy","studyType":"Clinical Study"}],"_fda":{"id":"043be80e-e80b-4332-ba7b-610e4a792059","set_id":"011473a8-26d5-4661-b3c0-745f9b6aa1d8","openfda":{"nui":["N0000184175","N0000009361","N0000010288"],"unii":["7SA290YK68","B697894SGQ","FZ989GH94E","0YZT43HS7D"],"route":["OPHTHALMIC"],"rxcui":["996202"],"spl_id":["043be80e-e80b-4332-ba7b-610e4a792059"],"brand_name":["GoodSense Eye Drops Advanced Relief Moisturizer"],"spl_set_id":["011473a8-26d5-4661-b3c0-745f9b6aa1d8"],"package_ndc":["68788-8635-1"],"product_ndc":["68788-8635"],"generic_name":["DEXTRAN, POLYETHYLENE GLYCOL 400, POVIDONE, TETRAHYDROZOLINE HCL"],"product_type":["HUMAN OTC DRUG"],"pharm_class_pe":["Increased Intravascular Volume [PE]"],"substance_name":["DEXTRAN 70","POLYETHYLENE GLYCOL 400","POVIDONE, UNSPECIFIED","TETRAHYDROZOLINE HYDROCHLORIDE"],"pharm_class_epc":["Plasma Volume Expander [EPC]"],"pharm_class_moa":["Osmotic Activity [MoA]"],"manufacturer_name":["Preferred PHarmaceuticals Inc."],"application_number":["M018"],"original_packager_product_ndc":["50804-130"]},"purpose":["Purposes Dextran 70.....Lubricant Polyethylene glycol 400.....Lubricant Povidone.....Lubricant Tetrahydrozoline HCl .....Redness reliever"],"version":"2","stop_use":["Stop use and ask a doctor if you experience • eye pain • changes in vision • continued redness or irritation of the eye, or if the condition worsens or persists for more than 72 hours"],"warnings":["Warnings For external use only Ask a doctor before use if you have narrow angle glaucoma Stop use and ask a doctor if you experience • eye pain • changes in vision • continued redness or irritation of the eye, or if the condition worsens or persists for more than 72 hours When using this product • pupils may become enlarged temporarily • to avoid contamination, do not touch tip of container to any surface. Replace cap after using. • if solution changed color or becomes cloudy, do not use • overuse may produce increased redness of the eye • remove contact lens before using If pregnant or breast-feeding , ask a health professional before use. Keep out of reach of children. If swallowed, get medical help or contact a Poison control Center (1-800-111-1222) right away."],"ask_doctor":["Ask a doctor before use if you have narrow angle glaucoma"],"when_using":["When using this product • pupils may become enlarged temporarily • to avoid contamination, do not touch tip of container to any surface. Replace cap after using. • if solution changed color or becomes cloudy, do not use • overuse may produce increased redness of the eye • remove contact lens before using"],"effective_time":"20250507","active_ingredient":["Active Ingredients Dextran 70.....0.1% Polyethylene glycol 400.....1% Povidone.....1% tetrahydrozoline HCl.....0.05%"],"inactive_ingredient":["Inactive ingredients benzalkonium chloride, boric acid, edetate disodium, purified water, sodium borate, and sodium chloride"],"indications_and_usage":["Uses • relieves redness of the eye due to minor eye irritations • as a lubricant to prevent further irritation or to relieve dryness of the eye"],"dosage_and_administration":["Directions Instill 1 to 2 drops in the affected eye(s) up to 4 times daily. Relabeled By: Preferred Pharmaceuticals Inc. NDC 68788-8635-1"],"spl_product_data_elements":["GoodSense Eye Drops Advanced Relief Moisturizer dextran, polyethylene glycol 400, povidone, tetrahydrozoline HCl BENZALKONIUM CHLORIDE BORIC ACID SODIUM BORATE POLYETHYLENE GLYCOL 400 POLYETHYLENE GLYCOL 400 TETRAHYDROZOLINE HYDROCHLORIDE TETRAHYDROZOLINE EDETATE DISODIUM EDETIC ACID POVIDONE, UNSPECIFIED POVIDONE WATER SODIUM CHLORIDE DEXTRAN 70 DEXTRAN 70"],"pregnancy_or_breast_feeding":["If pregnant or breast-feeding , ask a health professional before use."],"keep_out_of_reach_of_children":["Keep out of reach of children. If swallowed, get medical help or contact a Poison control Center (1-800-111-1222) right away."],"package_label_principal_display_panel":["Eye Drops Advanced Relief Moisturizer"]},"tags":[{"label":"Plasma Volume Expander [EPC]","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Ophthalmic","category":"route"},{"label":"Injectable","category":"form"},{"label":"Active","category":"status"},{"label":"redness of the eye due to minor eye irritations","category":"indication"},{"label":"further irritation","category":"indication"},{"label":"dryness of the eye","category":"indication"},{"label":"Allergan","category":"company"},{"label":"Approved 1970s","category":"decade"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"260 reports"},{"date":"","signal":"INFUSION RELATED REACTION","source":"FDA FAERS","actionTaken":"148 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"131 reports"},{"date":"","signal":"BACK PAIN","source":"FDA FAERS","actionTaken":"115 reports"},{"date":"","signal":"FLUSHING","source":"FDA FAERS","actionTaken":"106 reports"},{"date":"","signal":"CHEST PAIN","source":"FDA FAERS","actionTaken":"105 reports"},{"date":"","signal":"ANAPHYLACTIC REACTION","source":"FDA FAERS","actionTaken":"98 reports"},{"date":"","signal":"DIZZINESS","source":"FDA FAERS","actionTaken":"92 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"88 reports"},{"date":"","signal":"PRURITUS","source":"FDA FAERS","actionTaken":"82 reports"}]},"trials":[],"aliases":[],"company":"Allergan","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=DEXTRAN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:24:04.813507+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Dextran","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T00:24:13.349487+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:24:11.942377+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:24:03.438131+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DEXTRAN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:24:12.771594+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:23:59.135442+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:23:59.135495+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:23:59.135505+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:24:14.302110+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1697742/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:24:13.234431+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"M018","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:23:59.135511+00:00"}},"allNames":"goodsense eye drops advanced relief moisturizer","offLabel":[],"synonyms":["GoodSense Eye Drops Advanced Relief Moisturizer","DEXTRAN 70"],"timeline":[{"date":"19780731","type":"positive","source":"OpenFDA","milestone":"FDA approval (Allergan)"}],"approvals":[{"date":"19780731","orphan":false,"company":"ALLERGAN","regulator":"FDA"}],"brandName":"GoodSense Eye Drops Advanced Relief Moisturizer","ecosystem":[],"mechanism":{"moaClass":"Osmotic Activity [MoA]","modality":"Small Molecule","drugClass":"Plasma Volume Expander [EPC]","explanation":"","oneSentence":"","technicalDetail":"GoodSense Eye Drops Advanced Relief Moisturizer, a dextran-based plasma volume expander, increases the osmotic pressure of the aqueous humor to draw in water and electrolytes, thereby increasing the volume of the eye's fluid."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Dextran","title":"Dextran","extract":"Dextran is a complex branched glucan, originally derived from wine. IUPAC defines dextrans as \"Branched poly-α-d-glucosides of microbial origin having glycosidic bonds predominantly C-1 → C-6\". Dextran chains are of varying lengths."},"commercial":{"launchDate":"1978","_launchSource":"OpenFDA (19780731, ALLERGAN)"},"references":[{"id":1,"url":"https://api.fda.gov/drug/label.json?search=openfda.generic_name:\"DEXTRAN\"","fields":["mechanism","indications","adverse_reactions","contraindications","warnings","dosage"],"source":"OpenFDA Label"},{"id":2,"url":"https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:\"DEXTRAN\"","fields":["approvals","company"],"source":"OpenFDA Drugs@FDA"},{"id":3,"url":"https://clinicaltrials.gov/search?intr=dextran","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":4,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=dextran","fields":["publications"],"source":"PubMed/NCBI"},{"id":5,"url":"https://en.wikipedia.org/wiki/Dextran","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-31T10:18:18.887501","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:24:16.544802+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"dextran","indications":{"approved":[{"name":"redness of the eye due to minor eye irritations","source":"OpenFDA Label","regulator":"FDA"},{"name":"further irritation","source":"OpenFDA Label","regulator":"FDA"},{"name":"dryness of the eye","source":"OpenFDA Label","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07159074","phase":"PHASE2","title":"Repurposing Tilmanocept for Cardiac Sarcoidosis","status":"RECRUITING","sponsor":"Duke University","startDate":"2025-09-17","conditions":["Cardiac Sarcoidosis"],"enrollment":15,"completionDate":"2026-12-31"},{"nctId":"NCT07463248","phase":"PHASE2","title":"PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy","status":"NOT_YET_RECRUITING","sponsor":"Wang Xin","startDate":"2026-03-05","conditions":["Hepatocellular Carcinoma (HCC)"],"enrollment":64,"completionDate":"2029-01-31"},{"nctId":"NCT07423000","phase":"PHASE1","title":"A Phase 1 Study of PVT401 in Healthy Subjects","status":"NOT_YET_RECRUITING","sponsor":"Parvus Therapeutics, Inc.","startDate":"2026-04","conditions":["Inflammatory Bowel Disease (IBD)"],"enrollment":36,"completionDate":"2027-11"},{"nctId":"NCT07414199","phase":"PHASE4","title":"The Role of Ferric Carboxymaltose in the Treatment of Pediatric Iron Deficiency Anemia in the Emergency Department","status":"NOT_YET_RECRUITING","sponsor":"Children's Hospital of Orange County","startDate":"2026-01-31","conditions":["Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney Disease","Iron Deficiency Anaemia Due to Dietary Causes","Iron Deficiency Anemia Treatment","Iron Deficiency Anemia Secondary to IBD or Gastric Bypass","Iron Deficiency Anemias"],"enrollment":150,"completionDate":"2026-12-31"},{"nctId":"NCT07403877","phase":"PHASE2","title":"Neoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-02-01","conditions":["Colorectal Cancer (MSI-H)"],"enrollment":114,"completionDate":"2034-12-31"},{"nctId":"NCT06572423","phase":"NA","title":"Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy for Palliative Head and Neck Cancer Treatment (PULS-Pal)","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2024-10-25","conditions":["Head and Neck Carcinoma","Localized Head and Neck Carcinoma","Metastatic Head and Neck Carcinoma","Recurrent Head and Neck Carcinoma"],"enrollment":43,"completionDate":"2029-12-16"},{"nctId":"NCT05340465","phase":"PHASE2","title":"Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants","status":"RECRUITING","sponsor":"University of Washington","startDate":"2022-11-27","conditions":["Prematurity","Iron-deficiency","Iron Deficiency Anemia","Iron Malabsorption"],"enrollment":120,"completionDate":"2027-06-30"},{"nctId":"NCT06550362","phase":"PHASE4","title":"Daily Iron vs Every-other-day Iron for Pediatric Patients With IDA","status":"NOT_YET_RECRUITING","sponsor":"Loma Linda University","startDate":"2026-05","conditions":["Iron Deficiency Anemia"],"enrollment":100,"completionDate":"2027-05"},{"nctId":"NCT07014371","phase":"NA","title":"Alternative vs. Once-Daily Oral Iron Supplementation in Iron Deficiency Anemia (IDA)","status":"RECRUITING","sponsor":"Phramongkutklao College of Medicine and Hospital","startDate":"2025-06-09","conditions":["Iron Deficiency Anemia Treatment"],"enrollment":114,"completionDate":"2027-12-31"},{"nctId":"NCT06753916","phase":"PHASE2","title":"ExCrossV Multi Site Trial for Vascularized High Risk Keratoplasty","status":"RECRUITING","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2025-04-01","conditions":["Corneal Transplant Failure"],"enrollment":96,"completionDate":"2031-01-01"},{"nctId":"NCT07291947","phase":"PHASE1,PHASE2","title":"PULSAR Combined With Immunotherapy and Chemotherapy","status":"RECRUITING","sponsor":"Wang Xin","startDate":"2025-11-04","conditions":["Cholangiocarcinoma"],"enrollment":60,"completionDate":"2027-09-10"},{"nctId":"NCT03818854","phase":"PHASE2","title":"Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome","status":"COMPLETED","sponsor":"Michael A. Matthay","startDate":"2019-11-26","conditions":["Respiratory Distress Syndrome, Adult"],"enrollment":120,"completionDate":"2024-06-30"},{"nctId":"NCT04057833","phase":"PHASE1","title":"E-CEL UVEC Cells as an Adjunct Cell Therapy for the Arthroscopic Rotator Cuff Repair in Adults","status":"ENROLLING_BY_INVITATION","sponsor":"Hospital for Special Surgery, New York","startDate":"2019-11-20","conditions":["Rotator Cuff Tears","Muscle Atrophy or Weakness","Tendon Rupture - Shoulder","Safety Issues"],"enrollment":20,"completionDate":"2026-10"},{"nctId":"NCT06798454","phase":"PHASE1","title":"Single Ascending Dose Study to Evaluate Safety Tolerability, Pharmacokinetics, and Pharmacodynamics of PVT201 in Healthy Subjects and Patients (PBC/PSC)","status":"COMPLETED","sponsor":"Parvus Therapeutics, Inc.","startDate":"2024-10-15","conditions":["Primary Biliary Cholangitis (PBC)"],"enrollment":24,"completionDate":"2025-04-23"},{"nctId":"NCT06712745","phase":"EARLY_PHASE1","title":"Feasibility Study of Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy (PULSAR) for Cancers of the Central Lung","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2025-09-19","conditions":["Cancer, Lung","Metastasis"],"enrollment":30,"completionDate":"2028-12"},{"nctId":"NCT05846646","phase":"PHASE2","title":"Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC","status":"TERMINATED","sponsor":"ImmuneSensor Therapeutics Inc.","startDate":"2023-06-28","conditions":["Oligometastatic Disease"],"enrollment":6,"completionDate":"2024-09-16"},{"nctId":"NCT04268849","phase":"PHASE3","title":"Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient","status":"RECRUITING","sponsor":"Auerbach Hematology Oncology Associates P C","startDate":"2020-02-27","conditions":["Iron Deficiency Anemia"],"enrollment":104,"completionDate":"2026-02"},{"nctId":"NCT07173907","phase":"","title":"Epi-on CuRV and Epi-off aCXL Protocols in the Management of Keratoconus","status":"COMPLETED","sponsor":"Gemini Eye Clinic","startDate":"2016-01-01","conditions":["Keratoconus"],"enrollment":135,"completionDate":"2024-03-30"},{"nctId":"NCT07121595","phase":"PHASE2","title":"Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial","status":"RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2025-07-17","conditions":["Oral Cavity Squamous Cell Carcinoma","Stage I Lip and Oral Cavity Cancer AJCC v8","Stage II Lip and Oral Cavity Cancer AJCC v8","Stage III Lip and Oral Cavity Cancer AJCC v8","Stage IVA Lip and Oral Cavity Cancer AJCC v8"],"enrollment":50,"completionDate":"2030-07-01"},{"nctId":"NCT03991169","phase":"PHASE4","title":"Oral Iron in Children With Chronic Kidney Disease","status":"RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2019-04-19","conditions":["Chronic Kidney Insufficiency","Chronic Kidney Diseases"],"enrollment":40,"completionDate":"2028-12-31"},{"nctId":"NCT05292001","phase":"PHASE4","title":"Single-dose Intravenous Iron Therapy for Anemia After Orthopaedic Trauma","status":"RECRUITING","sponsor":"Oregon Health and Science University","startDate":"2022-06-01","conditions":["Acute Blood Loss Anemia","Fracture"],"enrollment":150,"completionDate":"2026-05-31"},{"nctId":"NCT07110935","phase":"PHASE1,PHASE2","title":"Efficacy of Treatment of Postpartum Anaemia With Intravenous Iron Versus Oral Iron in a Tertiary Hospital in South East, Nigeria.","status":"COMPLETED","sponsor":"Federal Teaching Hospital Abakaliki","startDate":"2018-09-13","conditions":["Postpartum Anaemia"],"enrollment":290,"completionDate":"2019-02-20"},{"nctId":"NCT07084298","phase":"EARLY_PHASE1","title":"Effects of Iron Supplementation on Skeletal Muscle Properties in Females With Suboptimal Iron Storage","status":"NOT_YET_RECRUITING","sponsor":"University of Calgary","startDate":"2025-08","conditions":["Iron Deficiency"],"enrollment":36,"completionDate":"2026-06"},{"nctId":"NCT07095244","phase":"NA","title":"Pediatric Outcomes and Recovery With Peri-Operative Iron Supplement Evaluation","status":"NOT_YET_RECRUITING","sponsor":"University of British Columbia","startDate":"2025-09-01","conditions":["Varus-Derotation Osteotomy Surgery","Iron-deficiency Anemia","Pelvic Osteotomy Surgery","Cerebral Palsy"],"enrollment":180,"completionDate":"2027-12-31"},{"nctId":"NCT06508827","phase":"PHASE2","title":"Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma","status":"WITHDRAWN","sponsor":"Indiana University","startDate":"2025-05","conditions":["Anemia, Iron Deficiency","Melanoma"],"enrollment":0,"completionDate":"2026-06"},{"nctId":"NCT06232434","phase":"PHASE2,PHASE3","title":"An Open Prospective Randomized Clinical Study of the Effectiveness, Tolerability and Safety of a Single Intraperitoneal Use of the Drug \"Prospidelong, Powder for the Preparation of a Gel for Topical Use, 1000 mg in Vials, Package No. 1\" in Patients With Disseminated Gastric Cancer, Phase I-II","status":"RECRUITING","sponsor":"Research Institute for Physical Chemical Problems of the Belarusian State University","startDate":"2025-06-20","conditions":["Gastric Cancer With Peritoneal Dissemination"],"enrollment":120,"completionDate":"2025-12"},{"nctId":"NCT05462704","phase":"PHASE3","title":"Intravenous Versus Oral Iron for Treating Iron-Deficiency Anemia in Pregnancy","status":"RECRUITING","sponsor":"Women and Infants Hospital of Rhode Island","startDate":"2023-01-17","conditions":["Iron Deficiency Anemia","Pregnancy"],"enrollment":300,"completionDate":"2027-03-31"},{"nctId":"NCT07005882","phase":"PHASE2","title":"Hormonal Receptor (HR)-Positive HER2 Negative Breast Cancer Patients Treated With Preoperative ELacestrant and PULSAR Radiotherapy","status":"NOT_YET_RECRUITING","sponsor":"Azienda Ospedaliero-Universitaria Careggi","startDate":"2025-09-01","conditions":["Breast Cancer Patients","Breast Cancer Early Stage Breast Cancer (Stage 1-3)","HR+/HER2- Breast Cancer","Radiation Therapy"],"enrollment":21,"completionDate":"2028-03-01"},{"nctId":"NCT06624709","phase":"NA","title":"The Benefit in Terms of Improvement in Haemoglobin Level at 6 Months in Premature Babies Receiving Alternate Iron Substitution 4 Times a Week Compared to a Daily Substitution","status":"RECRUITING","sponsor":"Riccardo Pfister","startDate":"2024-11-02","conditions":["Premature Birth"],"enrollment":160,"completionDate":"2027-05"},{"nctId":"NCT04526678","phase":"NA","title":"Oslo Footballplayers Iron Supplementation and Training (FIT) Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Norwegian University of Life Sciences","startDate":"2020-08-11","conditions":["Athletes","Iron","Endurance Performance","Hemoglobin","Intestinal Health","Microbiota"],"enrollment":26,"completionDate":"2030-12-31"},{"nctId":"NCT02235857","phase":"NA","title":"Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children","status":"RECRUITING","sponsor":"Kaneka Medical America LLC","startDate":"2015-05-03","conditions":["Focal Segmental Glomerulosclerosis"],"enrollment":35,"completionDate":"2028-07-03"},{"nctId":"NCT05678647","phase":"NA","title":"Sucrosomial Iron and Iron Sulphate to Blood Donors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Uppsala University Hospital","startDate":"2023-01-31","conditions":["Blood Donation"],"enrollment":120,"completionDate":"2026-01-01"},{"nctId":"NCT05167734","phase":"PHASE2","title":"Practical Anemia Bundle for SusTained Blood Recovery","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2021-11-30","conditions":["Anemia","Critical Illness"],"enrollment":100,"completionDate":"2024-11-26"},{"nctId":"NCT05008276","phase":"","title":"Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)","status":"RECRUITING","sponsor":"Petter Bjornstad","startDate":"2021-09-27","conditions":["Type 2 Diabetes Mellitus","Diabetic Kidney Disease","Adolescent Obesity","Pre Diabetes","Kidney Hypoxia","Puberty"],"enrollment":100,"completionDate":"2027-12-01"},{"nctId":"NCT03157167","phase":"PHASE1","title":"An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) and Subcutaneous (SC) Injection in Kaposi Sarcoma (KS)","status":"COMPLETED","sponsor":"Navidea Biopharmaceuticals","startDate":"2017-12-01","conditions":["Kaposi Sarcoma","HIV Infections"],"enrollment":15,"completionDate":"2020-03-30"},{"nctId":"NCT06835023","phase":"NA","title":"Dextran 40 Plus Ringer's Lactate Vs. Ringer's Lactate Alone for Fluid Resuscitation in Acute Pancreatitis","status":"RECRUITING","sponsor":"Satu Mare County Emergency Hospital","startDate":"2022-01-10","conditions":["Acute Pancreatitis (AP)","Acute Pancreatic Fluid Collection","Fluid Resuscitation"],"enrollment":100,"completionDate":"2025-05-12"},{"nctId":"NCT04793906","phase":"NA","title":"Meals to Improve Absorption of Iron Supplements","status":"COMPLETED","sponsor":"Pennington Biomedical Research Center","startDate":"2021-05-10","conditions":["Iron-deficiency","Iron Deficiency Anemia","Iron Deficiency Anemia Treatment"],"enrollment":59,"completionDate":"2024-11-01"},{"nctId":"NCT04097730","phase":"PHASE3","title":"Steroids and Cross-linking for Ulcer Treatment","status":"COMPLETED","sponsor":"Thomas M. Lietman","startDate":"2020-09-24","conditions":["Keratitis Bacterial"],"enrollment":280,"completionDate":"2024-09-18"},{"nctId":"NCT04466098","phase":"PHASE2","title":"Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2020-07-30","conditions":["Acute Respiratory Distress Syndrome","ARDS (Moderate or Severe)","COVID-19 Pneumonia"],"enrollment":8,"completionDate":"2024-12-31"},{"nctId":"NCT05246280","phase":"PHASE3","title":"Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA","status":"TERMINATED","sponsor":"Navidea Biopharmaceuticals","startDate":"2022-03-02","conditions":["Rheumatoid Arthritis"],"enrollment":169,"completionDate":"2024-07-09"},{"nctId":"NCT04497012","phase":"PHASE4","title":"Iron Supplementation and Intestinal Health","status":"UNKNOWN","sponsor":"University of South Florida","startDate":"2020-11-17","conditions":["Anemia of Prematurity","Very Low Birth Weight Infant"],"enrollment":183,"completionDate":"2025-07-31"},{"nctId":"NCT00560651","phase":"","title":"German Corneal Cross Linking Register","status":"ACTIVE_NOT_RECRUITING","sponsor":"Suphi Taneri","startDate":"2007-11","conditions":["Keratoconus"],"enrollment":7500,"completionDate":"2027-11"},{"nctId":"NCT05989984","phase":"NA","title":"Efficacy Evaluation of an ODF Iron Supplement Vs an Iron Supplement in Capsules in Subjects with Mild Anemia","status":"COMPLETED","sponsor":"IBSA Farmaceutici Italia Srl","startDate":"2023-07-29","conditions":["Iron Deficiencies"],"enrollment":23,"completionDate":"2024-08-08"},{"nctId":"NCT04947137","phase":"PHASE2","title":"Development of a Normative Database for Rheumatoid Arthritis (RA) Imaging With Tc99m Tilmanocept","status":"COMPLETED","sponsor":"Navidea Biopharmaceuticals","startDate":"2021-05-27","conditions":["Rheumatoid Arthritis"],"enrollment":134,"completionDate":"2022-01-21"},{"nctId":"NCT04078191","phase":"PHASE2","title":"Comparison of Tc 99m Tilmanocept Imaging With IHC Analysis of CD206 Expression in Synovial Tissue of Subjects With RA","status":"TERMINATED","sponsor":"Navidea Biopharmaceuticals","startDate":"2021-09-14","conditions":["Rheumatoid Arthritis"],"enrollment":20,"completionDate":"2024-07-09"},{"nctId":"NCT03332940","phase":"PHASE1","title":"Safety Evaluation of IV Tc 99m Tilmanocept and Comparison of Imaging With Sulfur Colloid in Subjects With and Without NASH","status":"TERMINATED","sponsor":"Navidea Biopharmaceuticals","startDate":"2017-12-06","conditions":["Nonalcoholic Steatohepatitis","NASH - Nonalcoholic Steatohepatitis"],"enrollment":6,"completionDate":"2019-03-10"},{"nctId":"NCT05846659","phase":"PHASE2","title":"Study of PULSAR-ICI +/- IMSA101 in Patients with Oligoprogressive Solid Tumor Malignancies","status":"TERMINATED","sponsor":"ImmuneSensor Therapeutics Inc.","startDate":"2023-07-07","conditions":["Oligoprogressive"],"enrollment":16,"completionDate":"2024-11-20"},{"nctId":"NCT06700824","phase":"PHASE2","title":"A Trial to Assess the Efficacy and Safety of OTR4132-MD in Patients with Acute Ischemic Stroke","status":"NOT_YET_RECRUITING","sponsor":"Organ, Tissue, Regeneration, Repair and Replacement","startDate":"2025-02","conditions":["Endovascular Thrombectomy","Ischemic Cerebrovascular Accident"],"enrollment":60,"completionDate":"2026-03"},{"nctId":"NCT06260618","phase":"NA","title":"Effect of Chitodex Gel in Tympanoplasty Surgery","status":"RECRUITING","sponsor":"Central Adelaide Local Health Network Incorporated","startDate":"2021-11-20","conditions":["Tympanic Membrane Perforation","Tympanic Membrane Inflammation","Surgery","Otitis Media"],"enrollment":44,"completionDate":"2025-05-13"},{"nctId":"NCT04691843","phase":"PHASE3","title":"Iron Supplementation and Neurodevelopmental Outcome in ELGANs","status":"COMPLETED","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2021-02-01","conditions":["Iron-deficiency"],"enrollment":51,"completionDate":"2024-08-31"},{"nctId":"NCT05870566","phase":"NA","title":"Pretreatment to Promote Graft Survival After Subsequent High-risk Corneal Transplantation [CrossCornealVision]","status":"RECRUITING","sponsor":"Claus Cursiefen","startDate":"2023-11-20","conditions":["Corneal Transplantation"],"enrollment":110,"completionDate":"2028-09-30"},{"nctId":"NCT05960227","phase":"PHASE2","title":"Effect of Intravenous Iron Repletion on Renal Function in Patients With Iron Deficiency and Acute Kidney Injury","status":"COMPLETED","sponsor":"Hospital Civil de Guadalajara","startDate":"2023-01-06","conditions":["Anemia, Iron Deficiency","Acute Kidney Injury"],"enrollment":120,"completionDate":"2024-09-30"},{"nctId":"NCT04484077","phase":"PHASE1","title":"hCT-MSC Infusion in Adults With Autism Spectrum Disorder","status":"COMPLETED","sponsor":"Joanne Kurtzberg, MD","startDate":"2022-01-24","conditions":["Autism Spectrum Disorder","Autism"],"enrollment":8,"completionDate":"2024-04-29"},{"nctId":"NCT02509598","phase":"PHASE2","title":"A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping","status":"COMPLETED","sponsor":"Cardinal Health 414, LLC","startDate":"2015-08","conditions":["Rhabdomyosarcoma","Melanoma"],"enrollment":24,"completionDate":"2019-03-06"},{"nctId":"NCT06359275","phase":"PHASE2","title":"PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-06-01","conditions":["Pancreatic Cancer"],"enrollment":81,"completionDate":"2027-10"},{"nctId":"NCT02889133","phase":"NA","title":"Donor Iron Deficiency Study - Red Blood Cells From Iron-deficient Donors: Recovery and Storage Quality","status":"COMPLETED","sponsor":"Columbia University","startDate":"2017-01","conditions":["Iron Deficiency"],"enrollment":79,"completionDate":"2021-10-05"},{"nctId":"NCT03438227","phase":"PHASE4","title":"Intravenous Iron for Iron-deficiency Anemia in Pregnancy: a Randomized Controlled Trial","status":"COMPLETED","sponsor":"Indiana University","startDate":"2018-04-15","conditions":["Iron Deficiency Anemia of Pregnancy","Iron Malabsorption"],"enrollment":38,"completionDate":"2019-12-31"},{"nctId":"NCT01604135","phase":"PHASE3","title":"Collagen Crosslinking for Keratoconus - a Randomized Controlled Clinical Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sahlgrenska University Hospital","startDate":"2012-05","conditions":["Keratoconus"],"enrollment":36,"completionDate":"2025-04"},{"nctId":"NCT06427070","phase":"NA","title":"Effectiveness of Two Intracanal Irrigation Solutions","status":"NOT_YET_RECRUITING","sponsor":"Misr University for Science and Technology","startDate":"2024-05-23","conditions":["Irreversible Pulpitis"],"enrollment":1,"completionDate":"2024-06-01"},{"nctId":"NCT04017598","phase":"PHASE4","title":"Potential Harms of Untargeted Iron Supplementation in Cambodia Where Iron Deficiency is Not the Cause of Anemia","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2019-12-10","conditions":["Anemia, Iron Deficiency","Anemia","Intestinal Inflammation","Inflammation","Intestine; Complaints"],"enrollment":480,"completionDate":"2023-12-01"},{"nctId":"NCT03041883","phase":"NA","title":"Corneal Collagen Crosslinking to Increase the Resistance of the Support Graft of the KPro Type I Against Corneal Melting","status":"RECRUITING","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2017-01-04","conditions":["Corneal Melting in Boston Keratoprosthesis Type I"],"enrollment":40,"completionDate":"2025-01"},{"nctId":"NCT06318858","phase":"NA","title":"Daily and Weekly Iron Supplementation in Infants","status":"RECRUITING","sponsor":"Mahidol University","startDate":"2023-03-15","conditions":["Anemia","Iron Status","Infants","Iron"],"enrollment":300,"completionDate":"2024-10-14"},{"nctId":"NCT03319082","phase":"","title":"Observational Registry to Assess the Durability of Effect of CXL in Patients With Corneal Ectasia After Refractive Surgery","status":"UNKNOWN","sponsor":"Glaukos Corporation","startDate":"2017-10-04","conditions":["Corneal Ectasia"],"enrollment":200,"completionDate":"2026-02"},{"nctId":"NCT05236387","phase":"","title":"Evaluating the Ability of 99mTc-Tilmanocept to Identify Clipped Nodes in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy and Sentinel Lymph Node Dissection","status":"TERMINATED","sponsor":"Johns Hopkins University","startDate":"2022-03-01","conditions":["Breast Cancer"],"enrollment":14,"completionDate":"2023-06-30"},{"nctId":"NCT04779489","phase":"NA","title":"Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer","status":"TERMINATED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2021-09-06","conditions":["Bladder Cancer"],"enrollment":1,"completionDate":"2023-06-02"},{"nctId":"NCT04096716","phase":"PHASE1","title":"Mapping Draining Lymph Nodes in CNS Malignancies","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2019-12-03","conditions":["Central Nervous System Neoplasms","Central Nervous System Tumor"],"enrollment":14,"completionDate":"2022-04-30"},{"nctId":"NCT04663126","phase":"EARLY_PHASE1","title":"Feasibility of IV Tc-99m-tilmanocept for Imaging of M2-like TAMs in Metastatic Melanoma","status":"TERMINATED","sponsor":"John O. Prior","startDate":"2021-02-01","conditions":["Melanoma"],"enrollment":5,"completionDate":"2023-06-19"},{"nctId":"NCT04293744","phase":"NA","title":"Acute Kidney Injury After Cardiac Surgery","status":"TERMINATED","sponsor":"XVIVO Perfusion","startDate":"2020-09-04","conditions":["Cardiac Surgical Procedures","Extracorporeal Circulation; Complications","Acute Kidney Injury"],"enrollment":100,"completionDate":"2023-10-31"},{"nctId":"NCT05446324","phase":"PHASE3","title":"Feasibility of Gallium-68-tilmanocept PET/CT for Sentinel Lymph Node Detection in Endometrial Cancer","status":"UNKNOWN","sponsor":"UMC Utrecht","startDate":"2023-02-15","conditions":["Endometrial Cancer"],"enrollment":10,"completionDate":"2024-09-01"},{"nctId":"NCT06147960","phase":"","title":"Prognostic Role of Inhibitor of Apoptosis Protein Overexpression on Recurrence Rate in Cervical Cancer","status":"UNKNOWN","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2023-11","conditions":["Cancer of Cervix","Apoptosis"],"enrollment":180,"completionDate":"2024-11"},{"nctId":"NCT04511026","phase":"PHASE2","title":"Concurrent Use Lymphoseek & Indocyanine Green in Sentinel Lymph Node Detection in Endometrial Cancer","status":"TERMINATED","sponsor":"Stanford University","startDate":"2021-01-20","conditions":["Endometrial Cancer"],"enrollment":6,"completionDate":"2021-06-10"},{"nctId":"NCT05007899","phase":"PHASE4","title":"Alternate Day Versus Daily Oral Iron Therapy in Adolescents","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2020-12-21","conditions":["Iron Deficiency Anemia","Heavy Menstrual Bleeding","Abnormal Uterine Bleeding"],"enrollment":13,"completionDate":"2022-12-22"},{"nctId":"NCT05047211","phase":"PHASE4","title":"Intravenous Iron vs. Oral Iron Supplementation for Postpartum Anemia","status":"COMPLETED","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2021-10-07","conditions":["Anemia, Iron Deficiency","Delivery Complication"],"enrollment":40,"completionDate":"2023-04-15"},{"nctId":"NCT06009575","phase":"PHASE3","title":"Local Culture-Based Nutrition Education Intervention on Iron Supplement Tablets (IST) Consumption Compliance in Female Adolescents at Ogan Komering Ilir Regency: A Quasi-Experimental Protocol Study","status":"COMPLETED","sponsor":"Universitas Sriwijaya","startDate":"2021-07-01","conditions":["Anemia","Iron Deficiency Anemia"],"enrollment":126,"completionDate":"2022-01-31"},{"nctId":"NCT03938636","phase":"PHASE2","title":"Evaluation of the Precision and Sensitivity of Tilmanocept Uptake Value (TUV) on Tc 99m Tilmanocept Planar Imaging","status":"COMPLETED","sponsor":"Navidea Biopharmaceuticals","startDate":"2019-04-08","conditions":["Rheumatoid Arthritis"],"enrollment":116,"completionDate":"2021-06-30"},{"nctId":"NCT02863809","phase":"PHASE1,PHASE2","title":"Vision Restoration With a Collagen Crosslinked Boston Keratoprosthesis Unit","status":"COMPLETED","sponsor":"Joseph B. Ciolino, MD","startDate":"2017-03-15","conditions":["Keratolysis"],"enrollment":76,"completionDate":"2021-08-31"},{"nctId":"NCT04371536","phase":"PHASE3","title":"Oral Iron Versus Oral Iron Plus a Web-based Behavioral Intervention in Young Children (IRONCHILD)","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2021-07-09","conditions":["Iron Deficiency Anemia","Iron-deficiency"],"enrollment":1,"completionDate":"2022-03-09"},{"nctId":"NCT05840848","phase":"NA","title":"Effect of Iron and Zinc Supplementation on B-carotene Bioavailability in Healthy Males","status":"COMPLETED","sponsor":"University of Hohenheim","startDate":"2017-11-21","conditions":["Bioavailability"],"enrollment":12,"completionDate":"2018-06-01"},{"nctId":"NCT04335058","phase":"NA","title":"Lactoferrin in Treatment of Fe Deficient Anemia In Cirrhosis","status":"UNKNOWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2020-01-01","conditions":["Iron Deficiency Anemia","Chronic Liver Failure"],"enrollment":130,"completionDate":"2023-12"},{"nctId":"NCT05743751","phase":"NA","title":"Normothermic Machine Perfusion (NMP) Versus Hypothermic Machine Perfusion (HMP) in Human Kidney Transplantation","status":"UNKNOWN","sponsor":"Zhang Tianyu","startDate":"2023-03-03","conditions":["Kidney Transplantation"],"enrollment":60,"completionDate":"2025-09-03"},{"nctId":"NCT04733664","phase":"NA","title":"Pilot Study to Evaluate Safety, Tolerability, and Performance of the FAST PV Technology™ in Chronic Dialysis Patients","status":"COMPLETED","sponsor":"FAST BioMedical","startDate":"2020-10-29","conditions":["End Stage Renal Disease"],"enrollment":10,"completionDate":"2021-03-09"},{"nctId":"NCT01464268","phase":"PHASE3","title":"Transepithelial Corneal Collagen Crosslinking for Keratoconus and Corneal Ectasia","status":"UNKNOWN","sponsor":"Cornea and Laser Eye Institute","startDate":"2011-11","conditions":["Keratoconus","Corneal Ectasia"],"enrollment":160,"completionDate":"2025-12"},{"nctId":"NCT01152541","phase":"PHASE3","title":"Corneal Collagen Crosslinking for Progressive Keratoconus and Ectasia Using Riboflavin/Dextran and Hypotonic Riboflavin","status":"UNKNOWN","sponsor":"Cornea and Laser Eye Institute","startDate":"2010-06","conditions":["Keratoconus","Corneal Ectasia"],"enrollment":160,"completionDate":"2025-12"},{"nctId":"NCT05714176","phase":"PHASE4","title":"Comparative Study Between Oral Liposomal Iron,Iron Supported Lactoferrin and IV Iron Dextran in CKD Children","status":"UNKNOWN","sponsor":"Menoufia University","startDate":"2023-02-01","conditions":["CKD - Chronic Kidney Disease"],"enrollment":90,"completionDate":"2024-12-31"},{"nctId":"NCT04584125","phase":"NA","title":"A Randomized Clinical Trial of Ex Vivo Corneal Cross-Linking of Donor Keratoplasty Tissue for Keratoconus Used for Keratoplasty in Keratoconus Patients","status":"NOT_YET_RECRUITING","sponsor":"Joseph B. Ciolino, MD","startDate":"2023-12-01","conditions":["Keratoconus"],"enrollment":216,"completionDate":"2028-11-30"},{"nctId":"NCT04897503","phase":"PHASE3","title":"Corneal Collagen Crosslinking for Keratoconus and Ectasia Using Riboflavin/Dextran or Riboflavin/Methylcellulose","status":"UNKNOWN","sponsor":"Cornea and Laser Eye Institute","startDate":"2021-04-16","conditions":["Keratoconus","Corneal Ectasia"],"enrollment":170,"completionDate":"2025-12"},{"nctId":"NCT03405142","phase":"PHASE2","title":"Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer","status":"COMPLETED","sponsor":"Eben Rosenthal","startDate":"2019-08-01","conditions":["Head and Neck Squamous Cell Carcinoma","Squamous Cell Carcinoma of the Head and Neck (SCCHN)","Head and Neck Cancer"],"enrollment":3,"completionDate":"2021-04-27"},{"nctId":"NCT05530356","phase":"","title":"Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study","status":"ENROLLING_BY_INVITATION","sponsor":"University of Colorado, Denver","startDate":"2022-09-30","conditions":["Type 2 Diabetes","Diabetes Type 2","Diabetic Nephropathies","Nephropathy","Obesity","Adolescent Obesity","Diabetic Kidney Disease"],"enrollment":100,"completionDate":"2029-05"},{"nctId":"NCT01743872","phase":"NA","title":"Optical Imaging Measurement of Intravascular Solution Efficacy Trial","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2012-09","conditions":["Peripheral Artery Disease"],"enrollment":23,"completionDate":"2016-06"},{"nctId":"NCT02791802","phase":"","title":"Effect of Lipoprotein(a) Elimination by Lipoprotein Apheresis on Cardiovascular Outcomes","status":"UNKNOWN","sponsor":"Technische Universität Dresden","startDate":"2016-08","conditions":["Lipoprotein Types--Lp System Lp(A) Hyperlipoproteinemia"],"enrollment":1000,"completionDate":"2022-12"},{"nctId":"NCT03843970","phase":"PHASE4","title":"Hemodynamic Safety of Levobupivacaine vs Bupivacaine in Patients Over 65 Years Undergoing Hip Surgery","status":"UNKNOWN","sponsor":"Hospital Clínico Universitario de Valencia","startDate":"2018-06-14","conditions":["Hip Fractures","Hemodynamic Stability"],"enrollment":150,"completionDate":"2023-07-31"},{"nctId":"NCT05266690","phase":"NA","title":"Effect of Degree of Polymerization and Linkage of α-glucans on Post-prandial Glucose Response","status":"COMPLETED","sponsor":"Société des Produits Nestlé (SPN)","startDate":"2019-11-29","conditions":["Postprandial Glucose Response"],"enrollment":10,"completionDate":"2020-02-18"},{"nctId":"NCT05181969","phase":"","title":"Long-term Characterization of Lipoprotein Apheresis Technologies for Individual Device Adaption (LOLIDA)","status":"UNKNOWN","sponsor":"Technische Universität Dresden","startDate":"2014-10-01","conditions":["Lipoproteinemia","Apheresis Related Complication","Cardiovascular Diseases"],"enrollment":500,"completionDate":"2024-12-31"},{"nctId":"NCT03808948","phase":"NA","title":"FAST PV and mGFR™ Technology in Congestive Heart Failure","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2019-01-10","conditions":["CHF"],"enrollment":50,"completionDate":"2019-08-17"},{"nctId":"NCT01084382","phase":"NA","title":"\" Arthrospira Platensis\" as Nutrition Supplementation for Female Adult Patients Infected by HIV in Yaoundé Cameroon","status":"COMPLETED","sponsor":"Frank Winter","startDate":"2010-04","conditions":["HIV"],"enrollment":70,"completionDate":"2010-09-10"},{"nctId":"NCT00000684","phase":"NA","title":"Continuous High-Dose Intravenous Dextran Sulfate in Human Immunodeficiency Virus-Infected Individuals","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":10,"completionDate":"1991-04"},{"nctId":"NCT00000690","phase":"PHASE1","title":"Single Dose Pharmacokinetics of Oral Dextran Sulfate (UA001) and Intravenous Dextran Sulfate in Healthy Volunteers","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":6,"completionDate":"1989-10"},{"nctId":"NCT00001009","phase":"PHASE1","title":"A Study of Dextran Sulfate in HIV-Infected Patients and in Patients With AIDS or AIDS Related Complex (ARC)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":60,"completionDate":"1990-04"},{"nctId":"NCT02165267","phase":"PHASE1","title":"Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-08","conditions":["HIV Infections"],"enrollment":88,"completionDate":"2016-02"},{"nctId":"NCT00789308","phase":"PHASE2","title":"Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-07-11","conditions":["Diabetes Mellitus, Type I"],"enrollment":24,"completionDate":"2014-08-21"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Ophthalmic","formulation":"Injectable","formulations":[{"form":"INJECTABLE","route":"OPHTHALMIC","productName":""}]},"crossReferences":{"UNII":"7SA290YK68","RXCUI":"996202","SPL_ID":"043be80e-e80b-4332-ba7b-610e4a792059","chemblId":"CHEMBL1697742"},"formularyStatus":[],"_enricherVersion":"v2-openfda","developmentCodes":[],"ownershipHistory":[{"period":"1978-","companyName":"Allergan","relationship":"Original Developer"}],"publicationCount":46950,"therapeuticAreas":["Ophthalmology"],"applicationNumber":"NDA017441","biosimilarFilings":[],"originalDeveloper":"Allergan","recentPublications":[{"date":"2026 Mar 30","pmid":"41912870","title":"The lipid transfer protein STARD7 controls intestinal tumor development in a context-dependent manner.","journal":"EMBO molecular medicine"},{"date":"2026 Mar 28","pmid":"41911983","title":"Ethnopharmacological basis and combined protection of intestinal barrier function by fucoidan from Sargassum thunbergii and chito-oligosaccharides in DSS-induced colitis.","journal":"Journal of ethnopharmacology"},{"date":"2025","pmid":"41909895","title":"Method of oral delivery affects vitamin C-mediated alleviation of colitis in a mouse model.","journal":"Gut microbes reports"},{"date":"2026 Jun 16","pmid":"41909465","title":"TIPE2 gene knockdown in mice attenuates experimental colitis by diminishing inflammatory cell infiltration.","journal":"Molecular therapy. Nucleic acids"},{"date":"2026","pmid":"41908945","title":"Cordycepin Ameliorates Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice by Inhibiting IL-6/IL-6R-Mediated p38 MAPK and NF-κB Activation Through Adenosine A(2A) Receptor Stimulation.","journal":"Drug design, development and therapy"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Allergan","companyId":"allergan","modality":"Oligosaccharide","firstApprovalDate":"1978","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1978-07-31T00:00:00.000Z","mah":"ALLERGAN","brand_name_local":null,"application_number":"NDA017441"},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":"ALLERGAN","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":"ALLERGAN","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":null,"mah":"ALLERGAN","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":"ALLERGAN","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":"ALLERGAN","brand_name_local":null,"application_number":null},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"ALLERGAN","brand_name_local":null,"application_number":""},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:24:16.544802+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}